PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 471/04, A61K 31/437, C07D 487/04, 211/34 // (C07D 471/04, 249:00, 221:00)

A1

(11) International Publication Number: **WO 00/06570**

(43) International Publication Date: 10 February 2000 (10.02.00)

(21) International Application Number: PCT/US99/16572

(22) International Filing Date: 21 July 1999 (21.07.99)

(30) Priority Data:

60/094,231	27 July 1998 (27.07.98)	US
Not furnished	15 July 1999 (15.07.99)	US

(71) Applicant *(for all designated States except US)*: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route 202, Raritan, NJ 08869 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HOEKSTRA, William, J. [US/US]; 2047 Stone Ridge Lane, Villanova, PA 19085 (US). LAWSON, Edward, C. [US/US]; 59 Whitemarsh Lane, Lansdale, PA 19446 (US). MARYANOFF, Bruce, E. [US/US], 4029 Devonshire, Forest Grove, PA 18922 (US).

(74) Agents: CIAMPORCERO, Audley, A., Jr et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08903–7003 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TRIAZOLOPYRIDINES FOR THE TREATMENT OF THROMBOSIS DISORDERS

(57) Abstract

The invention is directed to novel triazolopyridine derivatives which are useful as antagonists of GPIIb/IIIa. Pharmaceutical compositions comprising the triazolopyridine derivatives of the present invention, methods of treating conditions mediated by GPIIb/IIIa (e.g., methods for treating platelet–mediated thrombotic disorders) along with processes for making the compounds and novel intermediates are also disclosed.

162162

G00001